Sign in Subscribe
Cancer treatment

Golden Berry Compound Shows Promise in Lung Cancer Treatment

Strategic Insights

— 1 min read

A compound isolated from the golden berry, Physalis peruviana, has been found to inhibit the growth of human lung cancer cells through DNA damage, apoptosis, and G2/M arrest. The study, published in BMC Cancer, demonstrates that the compound, 4beta-Hydroxywithanolide E (4betaHWE), has potential as a chemotherapeutic agent against lung cancer. The researchers isolated the compound from the crude extract of the golden berry and investigated its antiproliferative effect on a human lung cancer cell line.

Key Takeaways:

  • The golden berry-derived compound, 4betaHWE, demonstrated a dose-dependent induction of DNA damage in human lung cancer cells (H1299) in a study published in BMC Cancer.
  • The compound induced apoptosis and G2/M arrest in lung cancer cells, indicating its potential as a chemotherapeutic agent.
  • The study's findings provide new insights into the cellular mechanism involved in the anti-hepatoma and anti-inflammatory activities of Physalis peruviana.
  • 4betaHWE was isolated from the crude extract of the golden berry and its antiproliferative effect was investigated on a human lung cancer cell line (H1299).
  • The alkaline comet-nuclear extract (NE) assay was used to evaluate the DNA damage caused by 4betaHWE.
  • The study's authors, Yen and colleagues, concluded that 4betaHWE is a potential DNA-damaging and chemotherapeutic agent against lung cancer.

Statistics:

  • 1, 5, and 10 microg/mL 4betaHWE induced significant DNA damage in lung cancer cells for 2 h in a dose-dependent manner (p<0.05).
  • The study used the human lung cancer cell line (H1299) to investigate the antiproliferative effect of 4betaHWE.
  • The alkaline comet-nuclear extract (NE) assay was used to evaluate the DNA damage caused by 4betaHWE.

Sources:

  • Yen, C.Y., et al. (2010). 4beta-Hydroxywithanolide E from Physalis peruviana (golden berry) inhibits growth of human lung cancer cells through DNA damage, apoptosis and G2/M arrest. BMC Cancer, 10(), 46.
  • Publisher's contact information for the journal BMC Cancer: Biomedical Central Ltd., Middlesex House, 34-42 Cleveland St., London W1T 4LB, England.

Read more